Is Ernexa Therapeutics Inc. (ERNA) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2024
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 8.9% / 30% | 22.4% / 30% | 5.7% / 30% | 42.78% / 5% | ✗ NOT HALAL |
| DJIM | 8.9% / 33% | 22.4% / 33% | 5.7% / 33% | 42.78% / 5% | ✗ NOT HALAL |
| MSCI | 13.0% / 33% | 32.8% / 33% | 8.3% / 33% | 42.78% / 5% | ✗ NOT HALAL |
| S&P | 8.9% / 33% | 22.4% / 33% | 5.7% / 33% | 42.78% / 5% | ✗ NOT HALAL |
| FTSE | 13.0% / 33% | 32.8% / 33% | 8.3% / 50% | 42.78% / 5% | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | 0.0% | |
| Operating Margin | 0.0% | |
| Net Margin | 0.0% | |
| Return on Equity (ROE) | -686.7% | |
| Return on Assets (ROA) | -104.9% |
Cash Flow & Balance Sheet
| Operating Cash Flow | -$16M |
| Free Cash Flow | -$16M |
| Total Debt | $684,000 |
| Debt-to-Equity | 20.4 |
| Current Ratio | 1.0 |
| Total Assets | $5M |
Price & Trading
| Last Close | $0.21 |
| 50-Day MA | $0.54 |
| 200-Day MA | $1.28 |
| Avg Volume | 1.7M |
| Beta | 6.9 |
|
52-Week Range
$0.20
| |
About Ernexa Therapeutics Inc. (ERNA)
Ernexa Therapeutics Inc., a preclinical-stage company, develops induces derived mesenchymal stem cells (iMSC) therapies for the treatment of treatment of cancer and autoimmune disease. The company's lead product is ERNA-101, an allogenic pro-inflammatory cytokine (IL-7/IL-15) secreting iMSC for the treatment of ovarian cancer; and ERNA-201, an anti-inflammatory cytokine (IL-10) secreting iMSC for the treatment of rheumatoid arthritis. It has a license agreement with Factor Bioscience Limited. The company was formerly known as Eterna Therapeutics Inc. and changed its name to Ernexa Therapeutics in March 2025. Ernexa Therapeutics Inc. was founded in 2018 and is based in Cambridge, Massachusetts.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is Ernexa Therapeutics Inc. (ERNA) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), Ernexa Therapeutics Inc. is Not Halal. The company fails one or more screening criteria. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is Ernexa Therapeutics Inc.'s debt ratio?
Ernexa Therapeutics Inc.'s debt ratio is 8.9% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 13.0%.
What are Ernexa Therapeutics Inc.'s key financial metrics?
Ernexa Therapeutics Inc. has a market capitalization of $6M, and revenue of $582,000. Return on equity stands at -686.7%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.